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Abstract
Aims/hypothesis The aim of our study was to identify sub-
groups of patients attending the Scottish Diabetic Retinop-
athy Screening (DRS) programme who might safely move
from annual to two yearly retinopathy screening.
Methods This was a retrospective cohort study of screening
data from the DRS programme collected between 2005 and
2011 for people aged ≥12 years with type 1 or type 2
diabetes in Scotland. We used hidden Markov models to
calculate the probabilities of transitions to referable diabetic
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retinopathy (referable background or proliferative retinopathy)
or referable maculopathy.
Results The study included 155,114 individuals with no
referable diabetic retinopathy or maculopathy at their
first DRS examination and with one or more further
DRS examinations. There were 11,275 incident cases
of referable diabetic eye disease (9,204 referable
maculopathy, 2,071 referable background or proliferative
retinopathy). The observed transitions to referable back-
ground or proliferative retinopathy were lower for peo-
ple with no visible retinopathy vs mild background
retinopathy at their prior examination (respectively,
1.2% vs 8.1% for type 1 diabetes and 0.6% vs 5.1%
for type 2 diabetes). The lowest probability for
transitioning to referable background or proliferative
retinopathy was among people with two consecutive
screens showing no visible retinopathy, where the prob-
ability was <0.3% for type 1 and <0.2% for type 2
diabetes at 2 years.
Conclusions/interpretation Transition rates to referable dia-
betic eye disease were lowest among people with type 2
diabetes and two consecutive screens showing no visible
retinopathy. If such people had been offered two yearly
screening the DRS service would have needed to screen
40% fewer people in 2009.
Keywords Diabetes . Diabetic retinopathy . Maculopathy .
Retinal screening . Screening intervals
Abbreviations
DRS Scottish diabetic retinopathy screening
IQR Interquartile range
SCI-DC Scottish Care Information–Diabetes
Collaboration
Introduction
Regular screening for proliferative retinopathy is
recommended for people with diabetes, as laser treatment
can prevent vision loss [1]. The Scottish Diabetic Retinop-
athy Screening (DRS) programme achieved national cover-
age in 2006 with the goal of annual screening of all people
aged ≥12 years with diabetes [2]. The key objective of the
service is to allow intervention with laser in patients with
proliferative retinopathy before sight is affected by vitreous
haemorrhage or retinal detachment. Retinal photographs are
not discriminatory for proliferative retinopathy or its pre-
cursors and so will also reveal signs of maculopathy. The
economic case for screening for diabetic macular oedema,
however, has not to date met the WHO criteria for system-
atic screening [3]. Despite this, more patients are referred
from the DRS to specialist ophthalmology care with
suspected diabetic macular oedema (maculopathy) than with
suspected proliferative retinopathy. Furthermore, the two
groups of patients are managed differently. Patients with
proliferative retinopathy, even those with normal vision,
are offered laser treatment, whereas patients with macular
oedema are increasingly only offered treatment if they have
symptomatic visual loss. This is because laser cannot restore
vision but, and perhaps equally important, once treatment
for proliferative retinopathy has been completed it does not
need repeating, whereas emerging treatment for macular
oedema will restore vision in many, but at the cost of
indefinite monthly intraocular injections [4, 5].
In the year April 2010 to March 2011 the DRS
programme examined 174,582 people (85% of the eligible
population) [6]. However, the prevalence of diabetes is
continuing to increase in Scotland (as in other parts of the
world) by an average of 4.2% per annum [7]. This increas-
ing demand requires a greater efficiency of current screening
practices including, amongst others, an optimal screening
interval for attendees.
Other groups have published on the subject of retinal
screening intervals. Iceland [8] and Sweden [9] have both
reported on their positive experiences of switching individ-
uals without evidence of retinopathy to longer screening
intervals. Recent publications from Iceland and Denmark
using modelling approaches to determine individualised
screening intervals suggested screening intervals incorporat-
ing a variety of measures beyond type and duration, such as
HbA1c, blood pressure and diabetes treatment ranging from
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6 months to 5 years [8, 10]. Data from the Welsh [11] and
English [12–14] diabetic retinopathy screening programmes
also support a move to lengthening the screening interval for
individuals without retinopathy.
The aim of this study was to use DRS programme data to
model the 1 and 2 year transition rates between the various
states of retinopathy, to establish the transition rates for
specific subgroups of the population screened according to
sex, diabetes duration and type of diabetes, and to establish
whether there are subgroups of the population at very low
risk of transition to the referable state of retinopathy in a
2 year interval.
Methods
The data used were from a pseudo-anonymised extract from
May 2008 of the Scottish Care Information–Diabetes Col-
laboration (SCI-DC), a clinical diabetes information system
which automatically collates clinical data from people diag-
nosed with diabetes in Scotland [15] and which has a current
estimated coverage of >99%. Ethical approval was obtained
from the Scotland A Research Ethics Committee, the
Caldicott (data privacy) Guardians for the 14 Scottish health
boards, and the National Health Service Information Services
Division Privacy Advisory Committee.
Eligible individuals (aged ≥12 years with a diagnosis of
diabetes and without suspensions) registered on SCI-DC are
invited either 6 monthly or annually to participate in the
DRS programme depending on the results at their previous
screening examination as described previously [16]. Since
2008, the DRS programme has consistently screened >80%
of the eligible population each year [6].
The Scottish grading system [17] classifies background
diabetic retinopathy, and thus the risk of progressing to
proliferative retinopathy, separately from the presence of
maculopathy. There are four possible outcomes from grad-
ing: (1) recall for a slit-lamp examination as the photographs
are ungradable; (2) recall in 12 months if the patient has no
visible retinopathy or only mild background retinopathy; (3)
recall in 6 months if the patient has observable background
retinopathy or observable background maculopathy; and (4)
referral to ophthalmology if the patient has proliferative
retinopathy, referable background retinopathy or refer-
able maculopathy. Actions are determined by the finding in
the worst eye. For this analysis we excluded examinations
which resulted in ungradable images. Slit-lamp examination
outcomes were not available for all health boards for the
whole time course of the study, but where slit-lamp data were
available they were included in the results.
The primary interest in the study was defined as transition
rate to any referable disease (which includes referable back-
ground and proliferative retinopathy, and those with referable
maculopathy). We performed subanalyses according to the
primary aim of retinal screening (the early detection of people
who have, or who are at risk of developing, proliferative
retinopathy), i.e. referable background or proliferative retinop-
athy (‘referable retinopathy’).
Study population This study was restricted to individuals
with type 1 or type 2 diabetes diagnosed prior to 31
May 2008. Individuals were included only if they had
an initial DRS examination which showed that the worst
eye had no visible retinopathy, mild background reti-
nopathy, observable background retinopathy or observ-
able maculopathy, and at least one subsequent DRS
examination. For baseline covariate data, to describe
the included population, we selected the measure from
SCI-DC taken nearest to the initial screening examina-
tion for BMI (kg/m2), HbA1c (% and mmol/mol), sys-
tolic and diastolic blood pressure (mmHg). In order to
limit missing covariate data while retaining a temporal rela-
tionship between measure and screening we used a series of
cut-points for time between screening and covariate
measure (HbA1c ±180 days, blood pressure ±90 days
and BMI ±1,085 days.)
Statistical methods For comparison of baseline variables we
used multiple linear and logistic regression models. All
statistical analyses were undertaken using the R statistical
package [18].
Multi-state modelling The DRS data consist of observations
of a continuous-time process (the progression of retinopa-
thy) at arbitrary times (i.e. at screening visits) and with
measurements that may not always perfectly reflect the
underlying pathology at the retina (i.e. disease may be
invisible to the naked eye/photography or misgraded by
retinal photography). Our objective was to model the so-
called transition intensity between the four observed states
of no visible retinopathy, mild background retinopathy, ob-
servable disease and referable disease as defined above. We
therefore fitted a hidden Markov model with misclassification
to the data using themsm package for R [19] and examined the
effect of individual level covariates on the transition intensities
between states. We then reported the model-based probabili-
ties of observing a transition to referable disease states in the
ensuing 1 and 2 year periods according to diabetes type, sex,
diabetes duration and observed retinal photograph grade at the
current screening examination, as all these characteristics
were shown to influence transition intensities and were avail-
able to the DRS at the time of screening. The electronic
supplementary material (ESM) gives more information on
msm model methods. From the fitted model, the probabilities
of the reported retinopathy states at screening after any spec-
ified time interval can be calculated for any individual, given
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the observations so far and the covariates for that individual.
We repeated the analysis of this four-state model with a five-
state model in which we further separated out referable back-
ground or proliferative retinopathy and referable maculopathy
into two states.
Results
There were 184,621 people with at least one successful DRS
examination between October 2005 and November 2011 (the
latest date for which data were available). From these we
selected those who did not have referable disease at their first
screening and whowere evaluable for progression (n=155,114;
84.0%). The median number (interquartile range [IQR]) of
examinations included in this study was four (IQR three to
five), with a median interval between successful examinations
of 12.7 months (IQR 12.1–13.9 months) (ESM Table 1).
Among those included in the analysis, the degree of
retinopathy at the initial DRS examination was related to a
number of factors including sex, age, diabetes duration,
glycaemia and blood pressure (Table 1). Median time be-
tween screening and measures of blood pressure, HbA1c and
BMI were 32, 51 and 148 days, respectively. Overall, re-
lationships shown were not affected by time between
screening and measurement of covariates, though if the
interval was limited to within 30 days associations between
blood pressure and retinopathy grades were no longer sta-
tistically significantly different.
Observed transitions Overall, there were 11,275 cases of
incident referable disease in the study, of which 2,071
(18.4%) were due to the presence of referable retinopathy;
the remaining 9,204 (81.6%) were due to referable
maculopathy. Of the cases of referable maculopathy, 526
(5.7%) were associated with the observable background
retinopathy grade, whereas the rest had either no visible
retinopathy or mild background retinopathy.
ESM Table 2 shows the frequency of the various states
by year of screening examination. There was a slightly
higher yield of referable cases in year 1, but in subsequent
years the percentage with referable disease was stable year
Table 1 Baseline demographics by initial retinopathy grade and diabetes type
Variable No visible
retinopathy
Mild
background
retinopathy
Observable
retinopathy or
maculopathy
p value* (no visible
retinopathy vs
mild background
retinopathy)
p value* (no visible
retinopathy vs
observable retinopathy
or maculopathy)
Type 1 7,869 (40.7%) 7,427 (38.4%) 784 (4.1%)
Male sex 4,131 (52.5%) 4,150 (55.9%) 442 (56.4%) <0.0001 0.0415
Age (years) 33.7±17.1 41.7±14.8 43.4±13.1 <0.0001 <0.0001
Diabetes duration (years) 7.1 (3.0–13.5) 18.8 (11.5–28.6) 20.8 (15.3–27.4) <0.0001 <0.0001
HbA1c <0.0001 <0.0001
% 8.6±1.8 8.7±1.6 9.2±1.6
mmol/mol 70.4±19.6 71.8±17.3 76.8±17.4
Systolic blood
pressure (mmHg)
126.5±17.2 130.2±17.2 132.4±17.9 <0.0001 <0.0001
Diastolic blood
pressure (mmHg)
73.8±10.4 74.6±9.9 76.3±10.4 0.0048 <0.0001
BMI (kg/m2) 25.7±5.5 27.0±5.0 27.6 ±5.2 <0.0001 <0.0001
Type 2 101,539 (68.5%) 35,227 (23.8%) 2,268 (1.5%)
Male sex 55,172 (54.3%) 20,407 (57.9%) 1,298 (57.2%) <0.0001 0.0066
Age (years) 64.4±11.8 64.6±11.6 65.1±11.2 0.0008 0.0024
Diabetes duration (years) 4.1 (1.6–7.5) 6.9 (3.2–12.0) 11.4 (6.4–16.5) <0.0001 <0.0001
HbA1c <0.0001 <0.0001
% 7.3±1.5 7.6±1.6 8.1±1.8
mmol/mol 56.7±16.1 59.9±17.3 64.8±19.5
Systolic blood
pressure (mmHg)
135.0±16.2 137.0±17.3 138.6±18.5 <0.0001 <0.0001
Diastolic blood
pressure (mmHg)
76.3±9.9 76.0±10.2 75.6±10.5 0.0003 0.0184
BMI (kg/m2) 31.6±6.4 31.4±6.3 31.4±6.2 0.1744 0.6282
Data are means±SD except for sex (n with percentage) and diabetes duration (median with IQR)
*p values computed by multiple logistic regression and controlled for sex and age, except for sex where p value was calculated using χ2 test
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on year at ∼5% for people with type 1 diabetes and ∼2% for
people with type 2 diabetes.
We calculated progression for both the ‘any referable
disease’ and ‘referable retinopathy’ endpoints. As referable
maculopathy accounted for the majority of the cases of
referable disease, the risk of progression to referable reti-
nopathy was always substantially lower for any given dia-
betes type, sex and duration. The percentage of those
transitioning between all possible consecutive examination
pairs during the entire follow-up period is summarised in
Table 2. As expected, the proportion transitioning to
referable disease from no visible retinopathy was far lower
than for those with mild background diabetic retinopathy
(0.6% vs 5.1% for any referable disease in type 2 diabetes),
whereas >20% of individuals with observable retinopathy or
maculopathy transitioned to any referable disease at their
next examination. Of note, there was also a striking amount
of regression, particularly at lower degrees of retinopathy.
For example, 18.2% of people with type 1 diabetes and
36.4% of people with type 2 diabetes transitioned from mild
background retinopathy to no visible retinopathy at their
subsequent examination.
Table 2 Observed transitions between states of retinopathy among diabetic patients undergoing retinal screening in the DRS programme
State at prior
assessment
State at next assessment Total pairs
No visible
retinopathy
n (%)
Mild background
retinopathy n (%)
Observable
retinopathy or
maculopathy n (%)
Referable
maculopathy
n (%)
Referable background
or proliferative
retinopathy n (%)
Type 1
No visible retinopathy 17,112 (76.5) 4,852 (21.7) 127 (0.6) 200 (0.9) 66 (0.3) 22,357 (100)
Mild background
retinopathy
3,950 (18.2) 14,912 (68.8) 1,059 (4.9) 1,374 (6.3) 386 (1.8) 21,681 (100)
Observable retinopathy
or maculopathy
78 (3.0) 834 (32.1) 1,056 (40.7) 483 (18.6) 144 (5.5) 2,595 (100)
Total 21,140 (45.3) 20,598 (44.2) 2,242 (4.8) 2,057 (4.4) 596 (1.3)
Type 2
No visible retinopathy 258,326 (85.9) 39,888 (13.3) 716 (0.2) 1,605 (0.5) 282 (0.1) 300,817 (100)
Mild background
retinopathy
37,912 (36.4) 58,339 (56.0) 2,617 (2.5) 4,457 (4.3) 808 (0.8) 104,133 (100)
Observable retinopathy
or maculopathy
773 (11.7) 2,367 (35.7) 2,024 (30.5) 1,085 (16.4) 385 (5.8) 6,634 (100)
Total 297,011 (72.2) 100,594 (24.4) 5,357 (1.3) 7,147 (1.7) 1,475 (0.4)
Distribution of observed results from pairs of consecutive examinations
Table 3 Probability of referable disease and referable background retinopathy or proliferative retinopathy at screening intervals of 1 or 2 years, by
sex, diabetes duration and current retinopathy grade in those with type 1 diabetes
Current grading Type 1
diabetes
duration
(years)
Men Women
Probability of any
referable disease (%)
Probability of
referable retinopathy (%)
Probability of any
referable disease (%)
Probability of referable
retinopathy (%)
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
No visible
retinopathy
0 – – – – – – – –
5 0.43 1.34 0.09 0.30 0.33 0.96 0.07 0.21
10 0.51 1.88 0.11 0.42 0.44 1.59 0.10 0.36
15 0.51 1.94 0.11 0.43 0.45 1.71 0.10 0.39
Mild background
retinopathy
0 – – – – – – – –
5 5.92 10.00 1.31 2.22 4.84 7.56 1.08 1.68
10 7.32 14.40 1.64 3.23 6.66 12.90 1.50 2.90
15 7.49 15.30 1.68 3.43 6.97 14.20 1.57 3.21
Referable disease: referable maculopathy, referable background retinopathy and proliferative retinopathy; referable retinopathy: referable back-
ground retinopathy and proliferative retinopathy
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To allow a simple graphical presentation of transitions,
the percentages transitioning to various states from a given
state over just the first three consecutive examinations are
shown in ESM Fig. 1a–f.
Probability of progression Fitting the hidden Markov model
yielded estimates of the rates at which the underlying dis-
ease states and the observed states differed, and the rates at
which these states regressed, given the modelling assumption
that transitions between these states arose from a Markov
process and that the ‘referable’ states did not regress. The
transition intensity matrix and emissionmatrix from the model
are shown in ESMTables 3 and 4 for type 1 diabetes and ESM
Tables 5 and 6 for type 2 diabetes. The relationship between
the retinopathy grades and the hidden states in the Markov
model is detailed in the ESM data file.
For both type 1 and type 2 diabetes, the risk of progres-
sion increased with the degree of retinopathy at last screen-
ing (Table 3 for type 1 diabetes and Table 4 for type 2
diabetes). The risk of progression at any given duration
and retinopathy grade was also consistently higher for peo-
ple with type 1 diabetes than for people with type 2 diabetes.
For type 1 diabetes, men had a higher risk than women at
each duration and retinopathy category, but for type 2 dia-
betes the risk estimates were similar for men and women.
For type 1 diabetes, the effect of duration was marked for up
to 10 years, after which duration had little effect on risk
estimates. People with a state of no visible retinopathy at
Table 4 Probability of referable disease and referable background retinopathy or proliferative retinopathy at screening intervals of 1 or 2 years, by
sex, diabetes duration and current retinopathy grade in those with type 2 diabetes
Current grading Type 2
diabetes
duration
(years)
Men Women
Probability of any
referable disease (%)
Probability of
referable retinopathy (%)
Probability of any
referable disease (%)
Probability of
referable retinopathy (%)
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
No visible
retinopathy
0 0.15 0.40 0.03 0.07 0.15 0.37 0.03 0.06
5 0.21 0.67 0.04 0.11 0.24 0.70 0.04 0.12
10 0.27 0.91 0.05 0.16 0.31 1.03 0.05 0.18
15 0.30 1.10 0.05 0.19 0.37 1.31 0.06 0.22
Mild background
retinopathy
0 2.79 4.43 0.47 0.75 2.52 5.59 0.43 0.63
5 4.08 7.41 0.69 1.26 4.06 6.96 0.69 1.19
10 5.10 10.20 0.87 1.74 5.43 10.40 0.93 1.78
15 5.80 12.20 0.99 2.08 6.43 13.20 1.09 2.25
Referable disease: referable maculopathy, referable background retinopathy and proliferative retinopathy; referable retinopathy: referable back-
ground retinopathy and proliferative retinopathy
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Fig. 1 Transition probabilities to referable background retinopathy
(R3) or proliferative retinopathy (R4) from no visible retinopathy by
sex and diabetes duration in type 1 diabetes for 1 or 2 yearly screening
intervals when last screening showed no visible retinopathy (a) and
when last screening showed no visible retinopathy but previous
screening showed mild background retinopathy (b). Blue filled
squares, men with 1 year screening interval; blue open squares, men
with 2 year screening interval; red filled circles, women with 1 year
screening interval; red open circles, women with 2 year screening
interval
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their last screening represented a group at low risk of 2 year
progression to any referable disease or referable retinopathy
in a 2 year interval. For example, at a duration of 10 years
men with no visible retinopathy and type 2 diabetes had a
risk of progression to any referable disease of 0.27% at
1 year and 0.91% at 2 years, with the corresponding risks
for referable retinopathy of 0.05% and 0.16%.
Figure 1a shows the probabilities of developing refer-
able retinopathy at either 1 or 2 year screening intervals
by sex for people with type 1 diabetes over a range of
diabetes durations if the current state was no visible
retinopathy. By contrast, the risks for the subset who
had mild background retinopathy at the examination
prior to a grade of no visible retinopathy are shown in
Fig. 1b and were clearly greater at all diabetes dura-
tions. The same was true for type 2 diabetes (Fig. 2a,b).
The probabilities of progression for those with no visi-
ble retinopathy at the current and previous examination
are shown in Table 5 for type 1 diabetes and Table 6
for type 2 diabetes. The lowest risk stratum for both
types of diabetes was those with a current and previous
state of no visible retinopathy. These patients had a very low
probability of referable disease or referable retinopathy in a
2 year interval regardless of diabetes duration.
Discussion
Potential loss of vision remains a major concern for people
with diabetes. Retinal screening programmes aim to enable
ophthalmic assessment and treatment to be focused on those
most at risk of future sight loss. This is particularly
0 5 10 15
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Fig. 2 Transition probabilities to referable background retinopathy
(R3) or proliferative retinopathy (R4) from no visible retinopathy by
sex and diabetes duration in type 2 diabetes for 1 or 2 yearly screening
intervals when last screening showed no visible retinopathy (a) and
when last screening showed no visible retinopathy but previous
screening showed mild background retinopathy (b). Blue filled
squares, men with 1 year screening interval; blue open squares, men
with 2 year screening interval; red filled circles, women with 1 year
screening interval; red open circles, women with 2 year screening
interval
Table 5 Probability of referable disease and referable background retinopathy or proliferative retinopathy at screening intervals of 1 or 2 years, by
sex, diabetes duration and previous and current retinopathy grade in those with type 1 diabetes
Previous and
current grading
Type 1
diabetes
duration
(years)
Men Women
Probability of any
referable disease (%)
Probability of referable
retinopathy (%)
Probability of any
referable disease (%)
Probability of
referable retinopathy (%)
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
No visible retinopathy,
no visible retinopathy
0 – – – – – – – –
5 0.19 0.81 0.04 0.18 0.14 0.56 0.03 0.13
10 0.24 1.13 0.05 0.25 0.20 0.93 0.04 0.21
15 0.24 1.16 0.05 0.26 0.21 0.99 0.05 0.22
Mild background retinopathy,
no visible retinopathy
0 – – – – – – – –
5 0.70 1.98 0.16 0.44 0.43 1.17 0.10 0.26
10 1.54 4.75 0.34 1.07 1.22 3.75 0.28 0.85
15 1.84 5.84 0.41 1.31 1.60 5.13 0.36 1.16
Referable disease: referable maculopathy, referable background retinopathy and proliferative retinopathy; referable retinopathy: referable back-
ground retinopathy and proliferative retinopathy
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important for proliferative retinopathy, which is asymptom-
atic until vitreous haemorrhage or retinal detachment occur.
At the outset of retinal screening programmes in the UK a
12 monthly screening interval was selected empirically [2,
20, 21], reflecting the hospital diabetes clinic tradition of
annual review for people with diabetes. Contemporary data
derived from screening programmes have been used to
define more optimal/individualised screening intervals
[8–14, 22, 23]. Here we report the largest and most compre-
hensive study to date. We show that men and women with
type 2 diabetes and no visible retinopathy at their last screen-
ing have a low risk of developing referable retinopathy within
a 1 year (≤0.06%) or 2 year screening interval (≤0.22%). If
two consecutive screenings showed no visible retinopathy, the
risks were even lower (≤0.03% after a 1 year interval and
≤0.15% after a 2 year interval even with a diabetes duration of
15 years). For a given screen finding of no visible retinopathy,
prior evidence of any retinopathy increased the rate of transi-
tion to referable disease in a 2 year interval approximately
sixfold, although it remained low in absolute terms. This is not
surprising as, although discrepancies between the observed
and underlying true state may occur through confusion with
photographic artefacts and the variability of human perfor-
mance, the changes in the retina that can be captured on
photographwill not always show the damage occurring within
the retina. For instance, capillary occlusion will cause
microaneurysms to thrombose followed by resorption of local
haemorrhage or exudate, and while capillary occlusion is
visible on fluorescein angiography it is not visible on retinal
photographs or to the naked eye. Transition to referable dis-
ease in a 2 year interval was higher in those with longer
duration of type 2 diabetes and in those with type 1 diabetes.
The primary strength of this study is that it uses data from
a national diabetic retinopathy screening service which in-
cludes longitudinal screening data for 155,114 people with
type 1 or type 2 diabetes. This makes it the largest study to
address the interval rates of disease to date. The DRS also
uses a centralised quality-controlled grading system, and the
criteria for referable disease have not altered over the course
of the programme. The choice of the hidden Markov model
approach used here was also flexible enough to allow for
inevitable imperfections inherent in using retinal photo-
graphs to assess retinopathy and maculopathy, and for co-
variate effects on the rate of progression of retinopathy. We
believe this is a better approach than use of life tables, Cox
proportional hazards models or interval censored survival
analysis because it captures both up and down transitions of
disease states which our data show are clearly occurring.
The modelling approach was also flexible enough to allow
for misclassified observations and covariate effects on the
rate of progression of retinopathy. For this analysis we
excluded examinations which resulted in an ungraded im-
age: over the course of the study 9,585 individuals had an
ungraded image (6.2% of study participants with ungraded
images), accounting for only 1.6% of screening episodes in
the study period. Thus, we do not think that excluding these
examinations greatly affected our findings.
Weaknesses of the study are that we do not as yet have
sufficient follow-up in the national programme to fully
examine the implications of extending screening intervals
beyond 2 years. Another potential weakness is that we do
not know the retinal status of patients prior to the first
screening episode within the DRS programme, which, as
we show, may influence subsequent risk. The msm package
Table 6 Probability of referable disease and referable background retinopathy or proliferative retinopathy at screening intervals of 1 or 2 years, by
sex, diabetes duration and previous and current retinopathy grade in those with type 2 diabetes
Previous and
current grading
Type 2
diabetes
duration
(years)
Men Women
Probability of any
referable disease (%)
Probability of referable
retinopathy (%)
Probability of any
referable disease (%)
Probability of
referable retinopathy (%)
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
1 year
interval
2 year
interval
No visible retinopathy,
no visible retinopathy
0 0.07 0.24 0.01 0.04 0.07 0.24 0.01 0.04
5 0.11 0.41 0.02 0.07 0.12 0.45 0.02 0.08
10 0.13 0.57 0.02 0.10 0.17 0.68 0.03 0.12
15 0.16 0.69 0.03 0.12 0.20 0.87 0.03 0.15
Mild background retinopathy,
no visible retinopathy
0 0.40 0.91 0.07 0.15 0.30 0.64 0.05 0.11
5 0.82 2.08 0.14 0.35 0.75 1.78 0.13 0.30
10 1.23 3.42 0.21 0.58 1.29 3.38 0.22 0.57
15 1.55 4.55 0.27 0.77 1.76 4.92 0.30 0.83
Referable disease: referable maculopathy, referable background retinopathy and proliferative retinopathy; referable retinopathy: referable back-
ground retinopathy and proliferative retinopathy
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also has some limitations. The fitting algorithm converges
only to a local mode of the likelihood: with different starting
values slightly different solutions are obtained. We specified
starting values that allowed the model to find a solution that
could be interpreted as a ‘misclassification’ model, in which
the observed scores roughly corresponded to the hidden
states with error. In practice, however, different starting
values gave similar risk predictions even though the under-
lying model variables were different.
We have chosen initially to provide results based on a
limited set of clinical data available to the DRS programme.
It is possible that further refinements of risk of progression
and thus safe screening interval can be determined by
adding additional clinical data, for example on diabetes
control, treatment regimen and other comorbidities such as
hypertension. Use of additional covariate data could allow
us to determine more ‘personalised’ screening intervals but
would not be possible to implement without direct connectiv-
ity of the DRS programme database to the clinical diabetes
database, which is not currently feasible.
One of the key questions to address when determining an
optimal screening window is what level of interval disease is
acceptable and this is to some extent arbitrary. The mean
grading sensitivity of the DRS programme in 2010 was
91.1% (SD 4.3) [24]. The annual referral rate for eye clinic
review is between 3.5% and 4.0% [25, 26]. Estimates of
annual screening rates for sight-threatening retinopathy
from elsewhere in the UK among individuals without reti-
nopathy at baseline are low, ranging from 0.01% [14] to
0.3% [12, 13]. We have shown here that in a group with no
visible disease at their two most recent screenings the prob-
ability of referable disease (both maculopathy and retinop-
athy) in a 2 year screening interval is low. Our findings
suggest that those with no visible retinopathy in both their
current and previous screening could be considered for
extending to 2 year screening intervals. Implementing a rule
of requiring two consecutive examinations with no visible
retinopathy before switching to a 2 year interval would
mean that 40% of all people screened in 2008 would have
been eligible to shift, with a reduction of 51,278 screening
examinations in 2009 and thus more efficient use of re-
sources. If we use the less stringent rule of having only the
last screening examination finding of no visible retinopathy,
63% of people screened in 2008 would have switched to
2 yearly screening, with a reduction of 81,230 screening
examinations in 2009. However, whilst overall rates of
incident disease in this subgroup are low, the rates at 2 years
are higher than at annual screening and alteration in the
screening interval will ultimately require consideration of
the ‘acceptable’ absolute rate of interval disease, especially
for proliferative retinopathy, as well as other factors such as
cost–benefits. In particular we should consider the possible
impact of reduced clinical contact and opportunities to use
detection of non-referable retinopathy and maculopathy for
improving overall diabetic control.
One striking element of the data is that there was a
considerable degree of regression in visible retinopathy
state especially in people with type 2 diabetes and lower
grades of retinopathy. This is likely in part to reflect progres-
sion of capillary occlusion leading to ‘disappearance’ of
microaneurysms followed by resorption of local exudate and
haemorrhage, rather than a true return to normal retinal perfu-
sion. However, the lack of newly forming microaneurysms to
replace those previously noted also suggests that in some
individuals the underlying disease process had improved.
We cannot tell at this stage if the level of regression seen here
was a result of improvements in the management of people
with diabetes particularly with regard to glycaemia and blood
pressure. Models that did not allow for regression had higher
deviance (poorer fit to the data).
This study shows that the increased risk of extending
the screening intervals for diabetic retinopathy for patients
with type 2 diabetes and no visible retinopathy after two
successive annual screening examinations is small. Possible
benefits of two yearly intervals include screening a greater
number of patients and/or enabling high-risk patients to
be screened more frequently. This work should help inform
policy-makers as to whether the benefits of two yearly screen-
ing for this group of patients outweigh the risks.
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